Akademisyen
ZİYA KALKAN
DOKTOR ÖĞRETİM ÜYESİ
DİCLE ÜNİVERSİTESİ TIP FAKÜLTESİ DAHİLİ TIP BİLİMLERİ BÖLÜMÜ
- Ana Dal Sağlık Bilimleri Temel Alanı
- Yan Dal TIP
Kayıtlı çıktılara kısa bakış — ayrıntılar aşağıda.
- Makale 32
- Proje 0
- Kitap 0
- Bildiri 7
- Patent 0
- Sanatsal 0
Scopus (SJR)
Q1
9
Q2
8
Q3
4
Q4
6
WoS (JCR)
Q1
5
Q2
5
Q3
12
Q4
6
TR Index
6
makale
Alan+yıl+tür normalize OpenAlex yüzdelik — Clarivate ESI / SciVal değildir.
Üst %1 makale
0
Üst %10 makale
4
Ort. yüzdelik
53.6%
Üst %1 payı
0.0%
Üst %10 payı
11.8%
Makaleler
YÖKSİS ve OpenAlex kaynak ayrımıyla makaleler; quartile ve TR Index ile daraltabilirsiniz.
Makale listesi
- 2026 Prognostic Significance of the CPS-EG Score in Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy YÖKSİS SJR Q1 JCR Q2 OpenAlex 71.8%
- 2025 Evaluation of treatment regimens and prognostic factors in primary central nervous system lymphomas YÖKSİS TR Index OpenAlex 71.8%
- 2025 Efficacy of Immunotherapy Versus Chemotherapy in Advanced Pleural Mesothelioma: A Turkish Oncology Group (TOG) Study YÖKSİS SJR Q2 JCR Q1 OpenAlex 86.0%
- 2025 Comparison of inflammatory indices in patients with metastatic non-small cell lung cancer YÖKSİS SJR Q3 JCR Q2 OpenAlex 62.8%
- 2025 Author Correction: The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study YÖKSİS SJR Q1 JCR Q1
- 2024 Causes of liver test abnormalities in newly diagnosed cancer patients and the investigation of etiological factors YÖKSİS SJR Q2 JCR Q1 OpenAlex 64.6%
- 2024 The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study YÖKSİS SJR Q1 JCR Q1 OpenAlex 53.9%
- 2024 Sequential Use of Sorafenib and Regorafenib in Hepatocellular Cancer Recurrence After Liver Transplantation: Treatment Strategies and Outcomes YÖKSİS SJR Q1 JCR Q2 OpenAlex 79.1%
- 2023 18 F-FDG PET/CT parameters for prediction of response to neoadjuvant therapy and prognosis in rectal cancer. YÖKSİS SJR Q3 JCR Q3 OpenAlex 72.3%
- 2023 Efficacy of pemetrexed plus a platinum rechallenge in the treatment of pleural mesothelioma YÖKSİS SJR Q4 JCR Q4 OpenAlex 11.1%
- 2023 Factors influencing the prognosis in Braf wild-type metastatic malignant melanoma and the role of novel inflammation indices YÖKSİS TR Index SJR Q4 JCR Q4 OpenAlex 46.1%
- 2023 Neoadjuvant Therapy and Factors Influencing Survival in Locally Advanced Non-Small Cell Lung Cancer YÖKSİS JCR Q3 OpenAlex 44.6%
- 2023 Comparison of Two Chemotherapy Regimens After First-Line Treatment for HER2-Negative Metastatic Gastric Cancer YÖKSİS JCR Q3 OpenAlex 11.9%
- 2023 Survival outcomes of patients diagnosed with muscle-invasive bladder cancer who showed a response after neoadjuvant chemotherapy and refused radical cystectomy, and patients who had radical cystectomy or received chemoradiotherapy YÖKSİS SJR Q4 JCR Q4 OpenAlex 20.5%
- 2023 Prognostic factors and the prognostic role of inflammation indices in malignant pleural mesothelioma. YÖKSİS SJR Q3 JCR Q4 OpenAlex 50.1%
- 2023 Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy YÖKSİS SJR Q2 JCR Q2
- 2023 Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy YÖKSİS SJR Q2 JCR Q2 OpenAlex üst %10 OpenAlex 94.2%
- 2023 Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group YÖKSİS SJR Q1 JCR Q1 OpenAlex 87.6%
- 2023 Comparison of the Efficacy and Safety of 3 Months of CAPOX Followed by 3 Months of Capecitabine and 6 Months of CAPOX/FOLFOX in the Adjuvant Treatment of Low-Risk Stage III Colon Cancer Treated Surgically YÖKSİS SJR Q2 JCR Q3 OpenAlex 43.9%
- 2022 Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study. YÖKSİS SJR Q1 JCR Q3 OpenAlex üst %10 OpenAlex 93.0%